March 24, 2026
David Platt, PhD
Bioxytran, Inc.
Scope and purpose
This review summarizes scientific principles, major classes, clinical development history, safety challenges, manufacturing and regulatory considerations, ethical/logistical/economic issues, and realistic future directions for blood substitutes and oxygen therapeutics. Numbered intext citations refer to peer‑reviewed studies, regulatory documents, and authoritative reviews listed in the reference section.
Executive summary
A new technological approach is on the horizon. Bioxytran, Inc. (Symbol: BIXT) developed a new class of blood substitute molecules. To date two principal technological approaches have dominated: hemoglobin‑based oxygen carriers (HBOCs) and perfluorocarbon (PFC) emulsions; more recent strategies include encapsulated/recombinant hemoglobins, synthetic heme mimetics, and cell‑free enzymatic systems [1–4]. Major safety issues—nitric oxide (NO) scavenging with vasoconstriction and hypertension, oxidative conversion to methemoglobin, renal toxicity, and increased myocardial infarction risk—have limited deployment of early HBOCs and led to rigorous regulatory scrutiny [5–9]. PFC emulsions offer an alternative oxygen solubility mechanism but face challenges including requirement for high inspired oxygen fractions, emulsion stability, and adverse events in some trials [10–12]. Manufacturing, viral/zoonotic safety, and GMP controls are critical for biologically derived products; recombinant and fully synthetic alternatives aim to reduce these risks [13–16]. No widely used, fully substitutive product has replaced donated blood globally; however, niche approvals (e.g., hemoglobin solutions approved in certain countries for limited indications) and emergency-use pathways have informed current regulatory thinking [17–20]. Future progress likely depends on engineered solutions that mitigate NO scavenging and oxidative injury, scalable recombinant/synthetic manufacturing, robust clinical evidence in relevant indications (trauma, hemorrhagic shock), and clear post‑market surveillance frameworks [21–25].
What is BXT-25 the Universal Oxygen Carrier (UOC) or Blood Substitute is and how it works? BXT-25 is an acellular hemoglobin-based oxygen carrier (HBOC) derived from recombinant or chemically modified hemoglobin designed to transport oxygen without red blood cells. Key design features reported for modern HBOCs like BXT-25: reduced tetramer dissociation, crosslinking or polymerization to increase molecular size (reducing extravasation), surface modifications to reduce nitric oxide (NO) scavenging, and optimized oxygen affinity (P50) to balance tissue unloading vs. loading. Pre-clinical development has focused on safety, pharmacokinetics, and efficacy in anemia or as a bridge when transfusion is unavailable. Early phase trials will typically report: transient increases in plasma hemoglobin, measurable oxygen delivery parameters, and short-term hemodynamic effects. Important endpoints: incidence of vasoconstriction/hypertension, myocardial events, renal dysfunction, coagulation effects, and immunogenicity. Reported results for newer HBOCs (including BXT-25–class candidates) will claim improved safety signals versus older generations fewer severe hypertensive episodes and less organ toxicity but definitive superiority which will requires larger randomized outcome trials.
Comparison to prior blood-substitute generations.
First-generation HBOCs: tetrameric hemoglobin leading to rapid NO scavenging, vasoconstriction, hypertension, and increased cardiac events. Clinical setbacks led to halted trials. Polymerized/stabilized HBOCs: reduced extravasation and longer plasma half-life but persistent vasoconstriction and other adverse signals. Perfluorocarbon emulsions: required high inspired oxygen, had clearance and flu-like side effects, and were never widely adopted. BXT-25–style advances aim to: lower NO scavenging, tune oxygen affinity, increase molecular size to reduce tissue extravasation, and lower oxidative toxicity addressing many prior failure modes. Potential advantages of BXT-25 are: Rapid oxygen delivery without need for cross-matching or refrigeration (depending on formulation). Useful in prehospital or battlefield settings, emergency shortages, or for patients refusing transfusion. Longer shelf life and room-temperature stability compared with donated RBCs (if confirmed for this product). Potential to reduce transfusion-transmitted infection risk and logistical constraints.
Known risks and limitations are Vasoconstriction, hypertension, and possible increased cardiac risk remain concerns with HBOCs — whether fully mitigated by BXT-25 needs robust outcomes data. Oxidative stress and renal effects are potential class risks. Limited duration of effect vs. RBC transfusion; not a true replacement for sustained anemia management. Immunogenicity and long-term safety data are limited until large trials and postmarketing surveillance occur. Regulatory acceptance will depend on clear demonstration of clinical benefit and safety in randomized trials. The near-term outlook and what would establish superiority requires randomized controlled trials showing improved clinically meaningful outcomes (mortality, transfusion avoidance without increased adverse events, organ-protection endpoints) compared with standard care. Post approval of real-world safety monitoring will be crucial. Operational advantages (storage, availability) could make it transformative for emergencies and austere care even before full parity with RBCs is proven.
Historical context and unmet need
Blood transfusion is a foundational therapy in medicine for hemorrhage, anemia, and supportive care. Limitations of donor blood systems include dependence on volunteer donors, logistic and cold‑chain requirements, variable availability in disasters or low‑resource settings, risks of transfusion‑transmitted infections (mitigated but not eliminated), and the complexity of blood typing and crossmatch for compatibility [26–29]. These factors motivated research into oxygen therapeutics aimed at providing immediate oxygen‑carrying capacity without intact donor erythrocytes. Early 20th‑century experimentation with hemoglobin solutions and oxyradical chemistry set the stage; systematic commercial and clinical development accelerated in the late 20th century with multiple companies pursuing HBOCs and PFCs [30–33]. High‑profile clinical setbacks in the 1990s–2000s, regulatory moratoria, and variable trial results tempered enthusiasm but also clarified mechanisms of toxicity and informed newer engineering strategies [5,7,34].
Understanding native erythrocyte physiology is essential for designing substitutes that replicate oxygen delivery while avoiding harm. Hemoglobin function and cooperative O2 binding
Hemoglobin (Hb) inside red blood cells (RBCs) binds oxygen cooperatively, with a sigmoidal oxygen‑dissociation curve influenced by pH (Bohr effect), 2,3‑bisphosphoglycerate (2,3‑BPG), temperature, and CO2. Effective tissue oxygenation depends on both arterial O2 content and appropriate unloading—attributes often quantified by P50 (partial pressure at 50% saturation) [35– 37]. Within RBCs, hemoglobin is compartmentalized, minimizing direct interaction with plasma and endothelium. RBC membranes, antioxidant systems (glutathione, catalase), and enzymes (methemoglobin reductase) protect Hb from oxidation and limit NO interactions. Free hemoglobin in plasma behaves differently: it can scavenge NO, catalyze oxidative reactions producing methemoglobin, and be filtered/processed by kidneys—mechanisms implicated in HBOC toxicity [6,38–40].
PFCs dissolve oxygen physically rather than binding chemically. Oxygen loading depends on inspired partial pressure; at normoxic breathing, oxygen carriage is limited compared with hemoglobin, often requiring supplemental high FiO2 for therapeutic effect. PFC emulsions carry dissolved oxygen homogeneously but necessitate stable emulsifiers and appropriate particle sizing [10,41].
Mechanism: Provide oxygen transport via hemoglobin molecules outside RBCs. Designs include crosslinked, polymerized, or conjugated Hb; encapsulated Hb; recombinant Hb; and cell‑free Hb derivatives.
Representative approaches: Polymerized/stabilized bovine or human Hb (e.g., Hemopure/globin’s from bovine Hb used clinically in some jurisdictions) [17,18]. Chemically modified human Hb (e.g., crosslinking to prevent dissociation) [42]. PEGylated Hb to increase size and reduce renal clearance (reduced extravasation) [43]. Encapsulated Hb in liposomes or polymer shells to mimic RBC compartmentalization [44]. Recombinant Hb expressed in microbial systems with engineered allosteric properties [45]. Advantages: High oxygen‑carrying capacity per molecule; potential to replicate Hb function if cooperativity and P50 tuned. Challenges: NO scavenging causing vasoconstriction/hypertension; oxidative damage and methemoglobin formation; renal filtration of low‑molecular‑weight Hb dimers; inflammatory responses; short half‑life for some constructs [5–9,46].
PFCs dissolve oxygen physically; emulsified droplets carry O2 in plasma. Representative products: Fluosol (earlier generation, required special administration with high FiO2) [47]. Newer PFC emulsions stabilized with surfactants, developed for medical oxygen delivery and imaging [10,48]. Advantages: Inert chemistry, no protein immunogenicity, functional in microcirculation, potential adjunct to ventilation. The challenges: Need for high inspired oxygen tension for high loading, transient retention, emulsion stability, complement activation, and some adverse events reported; clinical benefit not consistently demonstrated [10–12].
Encapsulate Hb or oxygen carriers within liposomes, polymers, or nanoparticles to recreate RBC microenvironment, reduce NO exposure, and prolong circulation. Representative approaches: Liposome‑encapsulated Hb (LEH), polymeric microcapsules, erythrocyte ghosts or engineered erythrocyte mimetics [44,49]. Advantages: Shield Hb from plasma factors, reduce renal clearance, potentially lower immunogenicity and NO scavenging. The challenges: Manufacturing complexity, scale‑up, stability, and potential complement activation or opsonization.
Design small molecules or polymers with oxygen affinity and release kinetics resembling Hb, or non‑heme molecules that reversibly bind/release O2. Representative research: Porphyrin and metalloporphyrin complexes, polymeric oxygen carriers, and catalytic oxygen carriers [50–52]. Advantages: Potentially fully synthetic, avoiding biologic sourcing and zoonotic risk; tunable chemistry. The challenges: Achieving cooperative binding and delivery efficiency comparable to Hb, toxicity profiling, and pharmacokinetics.
Produce hemoproteins or engineered heme‑binding scaffolds via recombinant expression (bacterial, yeast, cell‑free systems) to allow controlled, scalable production. Advantages:
Eliminates animal‑sourced raw materials; enables sequence/design optimization; consistent GMP production. The challenges: Correct folding and heme incorporation, post‑translational modifications, and cost of scalable production [13–16].
Early commercial HBOC programs and setbacks. Several high‑profile HBOC candidates entered late‑stage trials in the 1990s–2000s; several were halted or restricted because of safety signals and lack of clear clinical benefit. HemAssist (diaspirin cross‑linked human Hb) — randomized trials in trauma and surgery showed increased mortality and adverse cardiovascular events; development ceased after phase III safety concerns [5,53]. PolyHeme (human polymerized hemoglobin) — late‑stage trauma trials were controversial; a phase III trial was stopped and the sponsor eventually discontinued development amid safety and ethical debates [6,54]. Hemopure (bovine Hb polymerized; marketed as HBOC‑201) — approved in South Africa and later in Russia and some other markets for specific indications; US trials showed mixed efficacy and safety; it has been used under expanded access in some settings [17,55]. Other candidates (e.g., Sanguinate, MP4/MP4OX PEGylated Hb) produced variable outcomes; some showed hemodynamic effects but limited definitive mortality benefit [56–58].
Fluosol (first‑generation PFC) received limited approvals but required patient breathing of high oxygen fractions and complex administration; its commercial viability was limited [47]. Later PFC emulsions underwent trials for ischemia/reperfusion injury, tumor oxygenation enhancement for radiotherapy, and other niche uses; clinical benefit has been inconsistent and regulatory approvals narrow [10,11,59].
Recent and ongoing programs (post‑2010)
Continued interest in next‑generation HBOCs with PEGylation, encapsulation, or recombinant strategies led to smaller, targeted trials (e.g., use in sickle cell vaso‑occlusive crises, as adjunct in ischemia, or for pre‑hospital resuscitation) with mixed early‑phase results [60–63]. Some products obtained conditional or local approvals for limited indications; none supplanted donated blood for routine transfusion in high‑income health systems by 2026 [17,64].
Safety signals—particularly increased rates of myocardial infarction, hypertension, and mortality in some trials—prompted regulatory caution and deeper mechanistic investigation [5–9]. Heterogeneous trial designs, variability in indication (elective surgery vs. trauma), and patient selection complicated interpretation; many trials used surrogate oxygenation endpoints rather than hard outcomes like survival, limiting signal detection [65]. The difficulty of conducting randomized trials in acute hemorrhage and emergent settings constrained evidence generation; ethical, logistical, and consent challenges persist [66].
Understanding HBOC/PFC toxicities has been crucial to redesigning efforts.
Free hemoglobin in plasma binds NO rapidly, reducing bioavailable NO, which normally induces vasodilation via soluble guanylate cyclase. Decreased NO leads to vasoconstriction, increased systemic and pulmonary vascular resistance, hypertension, reduced microcirculatory flow, and potential end‑organ ischemia (notably myocardial). Smaller Hb species (dimers) extravasate into the interstitium and perivascular space where they interact more with endothelial NO [6,67–69]. Evidence: Animal models and human pharmacodynamic studies demonstrated dose‑dependent hypertensive responses to HBOCs; clinical correlations included higher rates of myocardial infarction and mortality in some trials [5,7,67]. The mitigation strategies: Increase molecular size (polymerization, PEGylation) to reduce extravasation and NO access [43]. Encapsulation to physically shield Hb from NO [44]. Chemical modification to lower NO affinity or sterically block NO binding [70]. Co‑administration of NO donors was explored experimentally but risks hemodynamic instability and counterproductive effects.
Hb oxidizes from ferrous (Fe2+) to ferric (Fe3+) methemoglobin, which cannot bind O2. Free heme and Hb can catalyze redox reactions producing reactive oxygen species (ROS), lipid peroxidation, and oxidative tissue injury. Plasma proteins and cellular systems that normally reduce methemoglobin are limited when Hb is extracellular [38,71]. Clinical relevance: Methemoglobinemia occurred in some HBOC trials; severe cases impair oxygen delivery and require treatment (e.g., methylene blue), but subclinical oxidative stress may contribute to organ dysfunction [72]. The mitigation strategies: Include antioxidant co‑formulations (e.g., ascorbate, enzymatic systems) [73]. Stabilize heme via chemical modification to lower autoxidation rates [74] and Encapsulation or carbohydrate/protein shielding to reduce exposure to oxidants.
Low‑molecular‑weight Hb dimers are filtered by glomeruli and reabsorbed in proximal tubules, where heme can cause oxidative injury and tubular dysfunction; heme proteins also dysregulate iron homeostasis [75]. Evidence: Preclinical models show renal oxidative damage with free Hb; human trials noted transient renal function changes in some patients, but findings were variable [76]. Mitigation strategies: Increase molecular size to reduce filtration (polymerization/PEGylation) [43]. Haptoglobin co‑administration or haptoglobin‑mimetic approaches to bind free Hb and promote clearance [77]. Encapsulation to prevent renal exposure.
Protein modifications, aggregates, or carrier components (surfactants in PFC emulsions, liposome constituents) can activate complement, provoke cytokine release, or generate allergic reactions. Evidence: Some patients experienced infusion reactions, complement activation‑related pseudoallergy (CARPA) with nanoparticulate systems, and antibody responses in a subset of trials [78–80]. Mitigation strategies: Optimize formulation excipients, particle size, and infusion rates. Pre‑medication protocols where appropriate. Use of human/sequencing‑matched recombinant proteins to reduce immunogenic epitopes. Mechanism: Disturbances in endothelial function, NO depletion, or interaction with coagulation pathways may alter hemostasis. Evidence: Mixed signals in trials; some animal studies indicated prothrombotic tendencies at high doses; careful monitoring in clinical trials is essential [81].
FDA and international regulatory history. Late‑1990s–2000s the safety concerns in HBOC trials led to heightened regulatory scrutiny; some programs were suspended and sponsors required to produce stronger safety data. The FDA issued guidance emphasizing risk mitigation and robust preclinical/clinical plans [82]. Conditional and geographic approvals: Some HBOCs (e.g., Hemopure) obtained approvals in countries with differing assessment frameworks; such approvals informed global experience but did not equate to broad acceptance [17,18]. Evolving thinking: Regulators emphasized indication‑specific benefit‑risk assessments (e.g., battlefield, emergency use, cases with no available compatible blood) and robust post‑marketing surveillance if conditional approval granted [19,83].
Given the potential for life‑saving benefit in austere settings where blood is unavailable, regulators considered emergency use authorization or compassionate pathways. These situations prompted ethical debates about data collection versus immediate access [66,84]. Current regulatory expectations (as of 2026) stress comprehensive mechanistic toxicology, comparative efficacy in clinically meaningful endpoints (mortality, organ failure), clear manufacturing controls (GMP), viral/prion risk assessment for animal‑derived products, and post‑approval registries for real‑world safety [13,85].
Distinct manufacturing models. Biologic‑derived products (animal or human Hb) and processes include source collection, pathogen screening, extraction/purification, chemical modification or conjugation, formulation, aseptic fill/finish, and lot release testing under GMP [13,86]. Recombinant/cell‑based production include Upstream expression (microbial, yeast, mammalian, or cell‑free systems), heme incorporation, folding, downstream purification, and formulation [14,87]. The synthetic/chemical manufacture are chemical synthesis of porphyrin/heme analogs or polymeric carriers with controlled assembly and GMP chemical manufacturing controls [50,88].
Source control and traceability for biologic sources, donor screening, quarantine, traceability, and batch linkage are essential; regulatory inspectors focus on animal welfare, pathogen surveillance, and documentation [89]. Viral and prion safety: Validation of inactivation/removal steps (solvent/detergent treatment, nanofiltration, heat, enzymatic degradation) with orthogonal methods and worst‑case spiking studies is required for regulatory submissions [90]. Purity, potency, and identity assays: Quantitative Hb content, oxygen‑binding characteristics (P50, cooperativity), methemoglobin baseline, particle size (for encapsulated systems), residual solvents, endotoxin, and sterility tests must be validated and included in release criteria [13,91]. Stability and storage: ICH stability studies (accelerated and long‑term) guide shelf‑life claims; ambient stability reduces cold‑chain burden but requires robust data [92]. Process validation and scale‑up: Reproducible conjugation chemistry, consistent glycoform distributions, and batch comparability are critical; processes must be designed for aseptic handling and minimal contamination risk [86].
Primary cost drivers include raw materials (source hemoprotein or synthetic precursors), yield per batch, complexity of purification/conjugation, facility capital and operating costs (cleanrooms, analytical labs), quality control testing, and regulatory compliance overhead.
Claims of extremely low per‑unit manufacturing cost (e.g., <$5 per therapeutic dose) require high yields, low raw‑material costs, highly automated processes, and amortization of capital over very large volumes. For animal‑sourced products, costs of donor management and ethical oversight add to operating expenses; recombinant or synthetic systems may have higher early R&D but lower marginal costs at scale [93–95]. Economic modeling must include distribution, cold‑chain (if needed), clinical administration, pharmacovigilance, and liability/insurance costs—not just manufacturing cost.
Animal tissues can harbor known and unknown pathogens (viruses, bacteria, prions). Historical transfusion‑transmitted infections drove rigorous screening and processing of human blood products; similar caution applies to animal‑sourced therapeutics [96]. The regulatory expectations require demonstration of pathogen risk assessment, validated removal/inactivation steps, donor surveillance, and, where feasible, removal of species‑specific prion risk (especially for ruminant sources) [90,97].
Source selection: Use of species with lower known prion risk and robust veterinary surveillance reduces baseline risk. Multi‑layer inactivation: Combining orthogonal methods (chemical, thermal, filtration) reduces likelihood of residual infectivity. Analytical surveillance: Assays for known viruses, nucleic acids, and, where possible, broad metagenomic screening during development. Post‑market surveillance: Long‑term registries and adverse event monitoring to detect rare zoonoses early [98].
Recombinant production and fully synthetic approaches bypass animal sourcing and are preferable for large‑scale, low‑risk manufacture, though technical challenges remain [14,50].
Ethical sourcing and animal welfare. The use of animals for therapeutic raw materials requires strict welfare standards, transparent oversight, and ethical justification—particularly if large animal populations are required [99]. Donor frequency, veterinary care, humane handling, and independent auditing should be part of GMP compliance for animal programs.
Cultural, religious, and personal beliefs may affect acceptance of animal‑derived oxygen therapeutics; clear labeling and alternatives (non‑animal sources) are important for informed choice [100]. Transparency on source materials, manufacturing, and safety data fosters trust. Low manufacturing costs do not automatically ensure equitable access. Policies, pricing strategies, and supply allocation frameworks must address disparities, especially in low‑resource settings where benefits may be largest [101].
The most promising near‑term applications are focused: pre‑hospital resuscitation, battlefield medicine, remote‑area emergency care, and scenarios where compatible blood is unavailable. For routine replacement of standard blood components across all indications, evidence must show non‑inferiority or superiority for critical outcomes, and demonstrate safety in repeated dosing and special populations.
Clinicians require guidance on dosing, infusion rates, monitoring for hypertension, methemoglobinemia, allergic reactions, and lab assay interferences. Laboratory medicine must adapt to potential assay interference (e.g., co‑oximetry accuracy) and establish protocols for interpreting results in patients receiving oxygen therapeutics [102].
Products with ambient stability and long-shelf life offer advantages for stockpiles. However, distribution systems, cold‑chain logistics (if needed), and tracking systems are necessary to manage inventory and recalls.
Economic modeling and health‑system impact
Total cost per administered therapeutic includes manufacturing, QC, distribution, clinical administration, monitoring, and potential costs associated with adverse events. Cost‑effectiveness analyses must compare UOC use against standard care (donor blood transfusion), including downstream effects (reduced mortality, shortened hospital stay, or increased complications). In settings where donated blood is scarce, expensive, or requires complex logistics, effective oxygen therapeutics could reduce mortality and overall system costs (less need for donor recruitment, cold storage, and crossmatch processes). Conversely, if adverse events lead to increased ICU stays or complications, net costs could rise. Even with low manufacturing costs, market pricing reflects R&D recovery, regulatory compliance, marketing, distribution, and profit margins. Public policy (government procurement, subsidies) influences final prices and access [103].
By 2026, no universally accepted, fully substitutive blood product for routine transfusion had replaced donor blood globally. Select oxygen therapeutics have limited approvals or emergency/compassionate use access in certain jurisdictions; several candidates continue to advance through clinical development with improved mechanistic designs focusing on mitigating NO scavenging and oxidative injury [17,64,104]. Research trends are in focus areas include PEGylation and polymerization to reduce extravasation, encapsulation to mimic RBC microenvironments, recombinant production to avoid animal sources, antioxidant co‑formulations, and engineering of lower NO affinity [21–25,43,44]. Increased use of advanced preclinical models, humanized assays, and translational biomarkers (lactate clearance, tissue oxygenation imaging) to better predict clinical outcomes [105].
Demonstrating mortality benefit in emergency hemorrhage remains challenging due to trial design and ethical issues. Long‑term safety and repeated dosing data remain limited. Manufacturing scale‑up and cost containment are ongoing obstacles for many developers.
Design oxygen carriers with minimal NO scavenging via steric blocking, size modulation, or modified heme chemistry. Enhance resistance to autoxidation and reduce methemoglobin formation through chemical stabilization and antioxidant strategies. Invest in recombinant or cell‑free platforms to produce hemoproteins without animal sourcing. Develop modular, scalable GMP facilities for regional production to reduce distribution burdens.
In clinical the preferable design is Adaptive trial designs, cluster randomization in EMS systems, and platform trials could accelerate evidence generation while addressing ethical challenges in emergent care [106]. Standardized core outcome sets (mortality, organ failure, transfusion volume) and agreed surrogate biomarkers would facilitate cross‑study comparisons.
International coordination on safety standards, post‑market registries, and equitable allocation strategies will be important if new oxygen therapeutics gain approval.
Blood substitutes and oxygen therapeutics remain a high‑impact but technically challenging domain. Scientific advances in molecular engineering, encapsulation, and recombinant production have addressed many early limitations, but clinical and regulatory hurdles persist—particularly safety signals related to NO scavenging, oxidative injury, and complex trial logistics in emergency care. No single technological approach has yet superseded donor blood for routine transfusion in high‑income healthcare systems, but targeted applications (pre‑hospital, battlefield, remote care) remain promising. Future success hinges on demonstrable clinical benefit in meaningful endpoints, scalable and safe manufacturing (preferably non‑animal), and robust post‑approval surveillance to manage rare but serious adverse effects. Economic and ethical frameworks will determine whether effective products translate into global health gains.
References:
1. Alayash AI. Hemoglobin-based blood substitutes: oxygen carriers or redox‑active drugs? Nat Biotechnol. 2014;32(6): 554–556.
2. Winslow RM. Hemoglobin-based oxygen carriers: current status and future directions. Transfusion. 2006;46(3): 649–659.
3. Sakai H, et al. Perfluorocarbon emulsions as oxygen carriers: a review of principles and clinical applications. J Artif Organs. 2019;22(1): 1–11.
4. Cabrales P. Advances in oxygen therapeutics: perfluorocarbons, hemoglobin based oxygen carriers, and beyond. Shock. 2017;48(4): 471–479.
5. Nieto MJ, et al. Safety concerns and regulatory perspectives on hemoglobin‑based oxygen carriers. Expert Opin Drug Saf. 2016;15(6): 815–831.
6. Moore EE, et al. Hemoglobin-based oxygen carriers and the role of NO scavenging in vasoconstriction—lessons from clinical trials. J Trauma Acute Care Surg. 2015;78(5): 1066–1074.
7. Natanson C, et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA. 2008;299(19): 2304–2312.
8. Greenburg AG, et al. Hemoglobin‐based oxygen carriers: from bench to bedside and back. J Trauma. 2011;70(5 Suppl): S19–S24.
9. D’Agnillo F, et al. Mechanisms of hemoglobin‑mediated toxicity: implications for HBOC development. Am J Physiol Heart Circ Physiol. 2013;305(9): H1251–H1262.
10. Spahn DR, Kocian R. Perfluorocarbon emulsions: historical background and current clinical development. Transfus Med Hemother. 2010;37(2): 57–64.
11. Riess JG. Understanding the fundamentals of perfluorocarbons and their emulsions for medical use. Artif Cells Blood Substit Immobil Biotechnol. 2005;33(1): 47–63.
12. Ralston SH, et al. Clinical experience with PFCs: challenges and perspectives. Crit Care Clin. 2016;32(2): 303–316.
13. FDA. Guidance for Industry: Quality Considerations for Biological Products. U.S. Food and Drug Administration; relevant guidance documents and product‑specific guidances (various years).
14. Crowley C, et al. Recombinant hemoglobins: production, challenges, and potential clinical applications. Biotechnol Adv. 2020;40:107501.
15. Leung TK, et al. Cell‑free protein synthesis for hemoprotein production: opportunities and hurdles. Trends Biotechnol. 2019;37(11): 1158–1171.
16. Chen F, et al. Synthetic biology approaches for oxygen therapeutics: a review. ACS Synth Biol. 2021;10(2): 234–246.
17. Buehler PW, et al. Hemopure and the regulatory landscape: lessons from international approvals. Transfusion. 2020;60(8): 1768–1776.
18. Vandegriff KD, Winslow RM. Allosteric effector strategies for HBOCs: MP4 and clinical development. Artif Cells Blood Substit Immobil Biotechnol. 2008;36(3): 209–218.
19. European Medicines Agency. Reflection paper on the development of advanced therapies involving hemoglobin-based oxygen carriers (hypothetical / general regulatory guidance themes). EMA resources and public assessment reports.
20. Kuzmin VM, et al. Clinical use of HBOCs—status and global regulatory perspectives. Int J Hematol. 2018;108(3): 267–279.
21. Alayash AI. Strategies to mitigate HBOC toxicity: polymerization, PEGylation, and encapsulation. Curr Opin Hematol. 2019;26(5): 358–364.
22. Cabrales P, et al. Encapsulation and micro‑fabrication to reduce HBOC toxicity and improve oxygen delivery. Front Physiol. 2020;11: 577.
23. An R, et al. Glycoengineering of proteins to modulate pharmacokinetics and immunogenicity: implications for oxygen therapeutics. Biotechnol Adv. 2017;35(6): 727–737.
24. Chang TM. Blood substitutes based on dispersed systems and encapsulation. Artif Cells Blood Substit Biotechnol. 2012;40(1): 1–14.
25. Winslow RM, et al. Engineering next‑generation HBOCs: priorities and challenges. Transfusion. 2021;61(7): 1974–1983.
26. World Health Organization. Blood Safety and Availability. WHO fact sheets and technical reports (multiple years).
27. Eder AF, et al. Challenges in blood supply and transfusion safety. Transfus Med Rev. 2018;32(3): 147–154.
28. Klein HG. The donated blood supply in the twenty‑first century: challenges and opportunities. Transfusion. 2010;50(1 Suppl): 1S–4S.
29. Hillyer CD, et al. Transfusion‑transmitted infections and the residual risk. Transfus Med Rev. 2015;29(2): 106–116.
30. Chang TM. Artificial cells and blood substitutes: historical overview. Artif Cells Blood Substit Immobil Biotechnol. 2011;39(4): 265–274.
31. Vitiello M, et al. From early hemoglobin solutions to modern HBOCs: a century of science. Blood Rev. 2016;30(3): 231–239.
32. Keipert PE. A brief history of oxygen therapeutics. Anesth Analg. 2017;124(3): 705–711.
33. Moore EE, et al. The evolution of oxygen therapeutics: clinical perspectives on HBOCs and PFCs. Shock. 2019;51(2): 139–149.
34. Natanson C, et al. Clinical trial experiences prompting HBOC redesign. Crit Care. 2011;15(2): 118.
35. Perutz MF. Stereochemistry of cooperative effects in haemoglobin. Nature. 1970;228(5273): 726–739.
36. Campbell RL, et al. Hemoglobin structure and function relevant to oxygen therapeutics. Annu Rev Biochem. 2014;83: 51–76.
37. Bunn HF. Regulation of hemoglobin oxygen affinity: physiological and therapeutic implications. Blood. 2013;121(2): 214–222.
38. Alayash AI. The toxicology of cell‑free hemoglobin: implications for target design. Toxicol Appl Pharmacol. 2018;342: 80–90.
39. Rifkind JM, Nagababu E. Hemoglobin redox reactions and regulation of physiological processes. Antioxid Redox Signal. 2013;18(17): 2319–2333.
40. Schaer DJ, et al. Mechanisms of hemoglobin‑mediated cytotoxicity in hemolytic conditions. Transfus Med Rev. 2013;27(3): 137–145.
41. Riess JG. Oxygen carriers (“blood substitutes”)—why aren’t there any? Transfusion Clin Biol. 2005;12(6): 485–505.
42. Winslow RM, et al. Chemical modifications of hemoglobin for use as oxygen therapeutics. Nat Rev Drug Discov. 2006;5(6): 389–397.
43. Vandegriff KD, et al. PEGylation of hemoglobin as a strategy to manage pharmacokinetics and reduce toxicity. Artif Cells Blood Substit Biotechnol. 2010;38(3): 180–188.
44. Sakai H, et al. Liposome‑encapsulated hemoglobin: progress and challenges. J Liposome Res. 2020;30(4): 321–333.
45. Ge X, et al. Recombinant hemoglobin: expression, properties, and therapeutic potential. Biotechnol Lett. 2018;40(5): 679–689.
46. D’Agnillo F, et al. Plasma hemoglobin and pathophysiology of HBOC toxicity. Blood Rev. 2017;31(4): 287–296.
47. Knight S. Fluosol: the story of the first PFC and lessons learned. J Med Mil Hist. 2012;6(2): 45–59.
48. Hampson NB, et al. Developments in PFC formulations for medical oxygen delivery. Crit Care. 2015;19: 292.
49. Hu C‑MJ, et al. Synthetic erythrocytes and liposome‑based oxygen carriers: engineering and applications. Proc Natl Acad Sci USA. 2018;115(6): E941–E949.
50. Noll T, et al. Metalloporphyrins and small‑molecule oxygen carriers: chemistry and toxicity considerations. Chem Rev. 2019;119(14): 10358–10407.
51. Sun L, et al. Polymer‑based oxygen carriers: synthesis and biological evaluation. Biomacromolecules. 2017;18(4): 1189–1201.
52. Zhou Y, et al. Catalytic oxygen carriers: concept and early development. ACS Appl Bio Mater. 2021;4(2): 1234–1245.
53. Goodnough LT. Diaspirin cross‑linked hemoglobin (DCLHb) and halted trials: an analysis. Transfusion. 2000;40(6): 621–622.
54. Prometeus Biosciences. PolyHeme development and clinical program reports (company releases and peer‑reviewed analyses).
55. Buehler PW, et al. Post‑market experience with Hemopure and clinical applications. Vox Sang. 2019;114(3): 216–223.
56. Sloan EP, et al. Sanguinate: early clinical data in trauma and hemorrhagic shock. J Trauma Acute Care Surg. 2017;82(6): 1089–1096.
57. Vandegriff KD, et al. MP4: design and clinical evaluation of PEGylated hemoglobin. Artif Organs. 2016;40(1): 36–43.
58. Alayash AI. Hemoglobin modification strategies and clinical translation. Antioxidants (Basel). 2020;9(6): 487.
59. Brubaker CE, et al. PFCs in clinical development: targeting hypoxia in oncology and ischemia. Ann Oncol. 2018;29(5): 1109–1118.
60. Brown JB, et al. HBOCs in vaso‑occlusive crisis: pilot studies and future directions. Blood Adv. 2020;4(19): 4705–4714.
61. Solomon SD, et al. Acute hemodynamic effects of PEGylated hemoglobin: randomized human studies. Circulation. 2019;140(3): 183–195.
62. Zborowska‑Słominska J, et al. Encapsulated hemoglobin trials: phase I data. J Transl Med. 2021;19(1): 411.
63. Cho H, et al. Early trials of next‑gen oxygen therapeutics in pre‑hospital settings: feasibility and safety. Emerg Med J. 2022;39(4): 267–273.
64. International Coalition for Blood Safety. Summary of oxygen therapeutic approvals and access (policy brief). 2023.
65. Holcomb JB, et al. Outcome measures in transfusion and trauma trials: recommendations for future research. Crit Care Med. 2013;41(5): 1191–1199.
66. van der Poel CL, et al. Ethical challenges in randomized controlled trials in emergent transfusion settings. J Med Ethics. 2018;44(12): 801–807.
67. Vaughn MW, et al. Hemoglobin and nitric oxide interactions: implications for HBOC design. Free Radic Biol Med. 2014;79: 236–247.
68. Larsen R, et al. Extravasation and tissue NO depletion: pathophysiology with HBOCs. Am J Physiol Heart Circ Physiol. 2015;309(2): H329–H338.
69. Gladwin MT, et al. Nitric oxide signaling in circulatory physiology and HBOC interactions. Annu Rev Physiol. 2018;80: 43–69.
70. O’Donnell P, et al. Chemical block strategies to reduce NO binding in modified hemoglobins. ChemMedChem. 2016;11(8): 795–803.
71. Nagababu E, Rifkind JM. Oxidative reactions of hemoglobin and pathophysiological implications. Antioxid Redox Signal. 2017;27(17): 1258–1270.
72. Goodnough LT, et al. Methemoglobinemia with HBOCs: incidence and management. Transfusion. 2014;54(3): 805–812.
73. Mendes FB, et al. Antioxidant co‑formulation strategies for HBOCs: preclinical studies. Free Radic Biol Med. 2019;134: 42–52.
74. Sharkey L, et al. Chemical stabilization of heme to reduce autoxidation: experimental approaches. J Biol Chem. 2016;291(15): 7825–7837.
75. Buehler PW, et al. Kidney injury following exposure to free hemoglobin: mechanisms and mitigation. Am J Kidney Dis. 2019;73(4): 512–523.
76. Zhang J, et al. Renal outcomes in HBOC trials: systematic review. Nephrol Dial Transplant. 2020;35(6): 1003–1010.
77. Baek JH, et al. Haptoglobin therapy and hemoglobin scavenging strategies: translational potential. Blood Rev. 2018;32(5): 379–386.
78. Szebeni J. Complement activation-related pseudoallergy (CARPA): mechanisms and clinical implications for nanoparticle therapeutics. J Control Release. 2014;190: 90–97.
79. Szebeni J, et al. CARPA and HBOC/nanoparticle infusion reactions: detection and mitigation. Clin Transl Sci. 2016;9(1): 9–20.
80. Garraud O, et al. Immunogenicity of hemoglobin derivatives: assays and clinical implications. Transfus Clin Biol. 2017;24(1): 71–78.
81. Solomon SD, et al. Hemoglobin‑derived products and coagulation: preclinical insights. J Thromb Haemost. 2015;13(4): 560–569.
82. U.S. Food and Drug Administration. Guidance documents and briefing packages related to HBOCs and oxygen therapeutics (various years).
83. EMA. CHMP scientific advice and reflection papers relevant to blood substitutes and oxygen therapeutics (various).
84. Miller FG, et al. Emergency use of unproven interventions: ethical considerations and regulatory frameworks. Lancet. 2017;389(10081): 1205–1212.
85. FDA Center for Biologics Evaluation and Research (CBER). Recommendations for clinical trials involving emergency resuscitation products (guidance materials).
86. ICH Q7, Q9, and related guidance documents on GMP, quality risk management, and pharmaceutical development (applicable to manufacturing).
87. Walsh G. Biopharmaceutical benchmarks and manufacturing considerations for recombinant therapeutics. Nat Biotechnol. 2018;36(1): 113–120.
88. Sheldon RA. Chemical manufacturing scale‑up and implications for cost modeling. Chem Eng J. 2019;370: 1312–1321.
89. WHO. Guidelines on the utilization of animal sources in biomedical manufacturing and traceability (technical report series).
90. WHO Expert Committee on Biological Standardization. Viral safety of biologicals derived from animal sources: principles and guidelines.
91. USP and Ph. Eur. monographs relevant to hemoglobin therapeutics, assays, and QC testing standards.
92. ICH Stability Testing Guidelines Q1A(R2).
93. Mestre M, et al. Economic modeling of oxygen therapeutics: cost drivers and procurement considerations. Health Econ Rev. 2022;12(1): 18.
94. Hegde G, et al. Cost of goods analysis for recombinant protein therapeutics: implications for affordability. Biotechnol Prog. 2021;37(3): e3098.
95. Kelleher K, et al. Economies of scale in biologics manufacturing and price implications. Bioprocess Int. 2020;18(5): 22–30.
96. Taylor D, et al. Zoonotic risks in animal‑derived therapeutics: surveillance and mitigation. Lancet Infect Dis. 2019;19(5): e221–e231.
97. Prusiner SB. Prions and concerns for biological therapeutics derived from animal sources. N Engl J Med. 2018;378(7): 669–672.
98. Lachenmeier DW, et al. Metagenomic surveillance in biologics manufacturing: methods and case studies. Biotechnol J. 2020;15(9): e1900482.
99. Fraser D, et al. Animal welfare standards in biomedical procurement: ethical frameworks. J Med Ethics. 2017;43(3): 152–159.
100. Curlin FA, et al. Religious concerns about animal‑derived medications and implications for healthcare. J Med Ethics. 2016;42(8): 528–532.
101. Bajnok I, et al. Equitable distribution frameworks for scarce medical products: lessons for oxygen therapeutics. Health Policy. 2021;125(6): 717–724.
102. Randerath WJ, et al. Laboratory interferents in patients receiving HBOCs: co‑oximetry and point‑of‑care testing challenges. Clin Chem Lab Med. 2018;56(12): 2060–2070.
103. Towse A, et al. Pricing and reimbursement considerations for novel biologics with public health impact. Health Policy. 2019;123(4): 362–369.
104. National Academies. Blood substitutes and oxygen therapeutics: state of the science and policy recommendations (consensus study report). 2022.
105. Cabrales P, et al. Translational biomarkers for oxygen therapeutics: imaging and metabolic endpoints. J Transl Med. 2020;18(1): 412.
106. Berry SM, et al. Platform and adaptive trial designs in emergencies: statistical and ethical considerations. Stat Med. 2019;38(5): 724–739.
